Zabalafin hydrogel (AB-101a) is in development to uniquely solve the critical challenges associated with treating mild-to-moderate atopic dermatitis (AD), the most common form of eczema. Developed with our proprietary, multi-target Zabalafin Platform, zabalafin hydrogel is a steroid-free topical with the potential to offer the first complete therapeutic for AD, targeting the immune system and bacterial components of the disease, with a safety, side effect and patient tolerability profile ideally suited for long-term, worry-free continuous use.
A Phase 2a clinical trial evaluating zabalafin hydrogel in adults and children (age 2 and up) with AD, in 2 cohorts, with and without infected AD skin, met all primary and secondary endpoints, demonstrating significant and clinically relevant improvements in itch, quality of life, inflammation, elimination of infected AD skin and control of Staph bacteria- associated and other AD Flares. This clinical trial demonstrated minimal side effects and excellent patient tolerability.
